Translate this page into:
Interobserver concordance of tumor-infiltrating lymphocyte assessment in triple-negative breast carcinoma; tissue microarray versus whole sections

*Corresponding author: Maher Sughayer, Department of Pathology, King Hussein Cancer Center, Amman, Jordan. msughayer@khcc.jo
-
Received: ,
Accepted: ,
How to cite this article: Sughayer M, Barakat F, Sweidan E, Maraqa B, Alsughayer A. Interobserver concordance of tumor-infiltrating lymphocyte assessment in triple-negative breast carcinoma; tissue microarray versus whole sections. CytoJournal. 2025;22:95. doi: 10.25259/Cytojournal_116_2025
Abstract
Objective:
Tumor-infiltrating lymphocyte (TIL) assessment is recognized as an important prognostic and therapeutic biomarker in several tumors, including triple-negative breast cancer (TNBC). TILs face several challenges, including low to intermediate interobserver concordance. The use of tissue microarray (TMA) in TIL assessment and its relationship/concordance with whole sections (WS) has been studied only rarely. The aim of this study is to evaluate the reproducibility of TIL assessment in TNBC among various users and to compare TIL assessment using TMA versus whole tissue sections (WS).
Material and Methods:
Hematoxylin and eosin-stained sections of TMAs were prepared and assessed for quality and adequacy. Corresponding WS slides for all cases were retrieved and independently scored for TILs by one junior and two senior pathologists. The assessment followed the guidelines of the International TILs Working Group. TIL scores were categorized into three groups: Low: <20%; intermediate: 20–49%; and high: ≥50%. A total of 100 cases were collected; however, 76 cases were evaluable after excluding inadequate samples or cases with missing information.
Results:
Fleiss’ kappa was used to assess interobserver agreement among the three raters for both WS and TMA datasets. The Intraclass Correlation Coefficient (ICC) was used to assess the degree of agreement among the three raters for continuous variables before categorization, and Cohen’s kappa was applied to both WS and TMA datasets to assess interobserver agreement between any two raters. The interobserver agreement for WS analysis (Cohen’s kappa) was fair, while for TMA, it was moderate. The ICC also showed moderate agreement. Cohen’s kappa for TMA versus WS for each of the three observers ranged from fair to strong. Fleiss’ kappa showed fair agreement for WS versus TMA.
Conclusion:
Interobserver variability in TIL scoring remains a challenge. TMAs improve consistency but at the cost of reduced correlation with WS assessments.
Keywords
Breast carcinoma
Concordance
Tissue microarray
Triple-negative
Tumor-infiltrating lymphocytes
INTRODUCTION
Occurring in every country of the world, breast cancer (BC) is the most diagnosed type of cancer in women, with an absolute total number exceeding 2 million cases in 2022, according to the International Agency for Research on Cancer, causing more than 600,000 deaths globally in 2022. Approximately 99% of BCs occur in women and 0.5–1% occur in men. It is the second-highest occurring cancer worldwide and the fourth-highest as cause of death. Industrial, well-developed countries lead worldwide with the most cases, whereas BC deaths are mainly in third-world countries.[1-3]
Reasons for the decline in mortality rates in Western Europe, Australia, and the United States include widespread mammographic screening, precise diagnosis, and an increased number of women receiving the best treatment for their conditions, including the extensive use of tamoxifen in cases of estrogen receptor (ER) positive subtypes.[4]
Statistically, approximately 60% of patients diagnosed with BC have hormone receptor-positive BCs, 20% have human epidermal growth factor receptor 2 (HER2)/neu receptor overexpressed, and 20% have triple-negative BCs (TNBC).[5,6]
Conventionally, TNBC encompasses a subset of BC that lacks the expression of ER, progesterone receptor (PR), and HER2.[7] Consequently, conventional hormonal/endocrine therapy treatments used for other BC subtypes are not effective, which calls for special treatment approaches. Certainly, of a much more aggressive biological behavior, TNBC is associated with a higher risk of distant metastases, higher rates of recurrence, and worse overall survival (OS) compared to other subtypes.[8,9]
Reports show that nearly 35% of patients with TNBC are diagnosed with distant metastatic lesions within 5 years of the first BC diagnosis.[10] In addition, the overexpression of the EGFR protein specific to TNBC, when compared with other subtypes of BCs, usually increases resistance of these types of cancer cells to conventional therapies.[11]
Despite this, our immune system provides support, as the presence of tumor-infiltrating lymphocytes (TILs) is associated with better prognosis. The immune system typically plays a crucial role in preventing tumor formation, and cancer progression often involves mechanisms that allow tumors to evade immune detection. Advances in immunotherapy have significantly improved outcomes in various solid tumors. Compared to hormone receptor-positive BC, TNBC is more immunogenic, and the immune microenvironment’s components have been correlated with favorable prognostic features. This has sparked growing interest in studying immune-modulating therapies for this BC subtype.[12]
TNBC is also marked by a high mutation rate and increased TILs, which are key adaptive immune cells within the tumor microenvironment. TILs are observed in about 20% of TNBC cases, appearing both within the tumor and in the surrounding stromal tissue. Their presence has both prognostic and predictive significance.[13,14] Multiple large clinical trials have shown that higher TIL levels correlate with better disease-free survival, OS, and pathological complete response rates following neoadjuvant chemotherapy in early TNBC.[15,16] An analysis of two phase III adjuvant trials indicated that each 10% increase in TILs corresponds to roughly a 15% reduction in recurrence and mortality.[16]
In addition, TILs may help predict immunotherapy response. In the KEYNOTE-086 trial, elevated TIL levels were linked to a significantly higher objective response rate to pembrolizumab.[17] TILs have also been investigated as a biomarker in metastatic TNBC, where higher levels are associated with improved outcomes. KEYNOTE-119 further demonstrated that TIL levels of ≥5% could predict better responses to pembrolizumab in this setting.[18]
Given these promising prognostic findings, the 2019 St. Gallen International Consensus guidelines recommend routine assessment of TILs in TNBC cases.[19]
The use of tissue microarrays (TMA) in evaluating TILs has been studied previously.[20] The performance of TMA as compared to whole sections (WS) is acceptable in general.
This study aims to evaluate the interobserver reproducibility of TIL assessment in TNBC and compare TIL scoring between TMA and whole tissue sections.
MATERIAL AND METHODS
Ethical approval
This retrospective study was approved by the Institutional Review Board (IRB) at King Hussein Cancer Center, Amman, Jordan.
TMA
TMAs were previously constructed from formalin-fixed, paraffin-embedded tumor samples collected from consecutive cases of TNBC diagnosed at a referral cancer center between 2015 and 2021. These TMAs had been initially prepared for prior research studies on BC.[21]
TILs assessment
Sections from the TMAs were cut at 4 µm thickness using HistoCore Leica RM2235 microtome and stained with hematoxylin and eosin (H&E) using the HistoCore SPECTRA H&E staining system S2 (Product number: 3801655; Leica Biosystems, Richmond, USA). All sections were assessed for tissue quality and tumor adequacy. In addition, corresponding WS, H&E-stained slides were retrieved for all cases. Before scoring, all pathologists underwent a calibration training session using resources available online from the International TILs Working Group. All slides were independently scored for TILs by one junior and two senior pathologists. The assessment was done according to the International TILs Working Group system. TIL scores were divided into three categories; low: <20%, intermediate: 20–49%, and high: ≥50% and examined using standard light microscopy [Figure 1].[22]

- Representative hematoxylin and eosin (H&E)-stained images (×10 magnification) of three triple-negative breast cancer cases evaluated for tumor-infiltrating lymphocytes (TILs). (a) High TIL score (≥50%), (b) intermediate TIL score (20–49%), and (c) low TIL score (<20%). Scale bar: 0.5 mm.
Demographics and clinicopathological variables were collected from patients’ electronic medical records.
Statistical assessment
Although no formal power calculation was conducted, the sample size aligns with similar interobserver concordance studies. A post hoc estimation was performed to assess whether the sample size (n = 76) would be adequate to detect a clinically meaningful difference of Δκ = 0.15 between WS and TMA. Assuming a two-sided alpha of 0.05, 80% power, and a baseline kappa of 0.40 (fair agreement), the minimum sample size required per group would be approximately 73 cases, as derived from formulas for comparing dependent kappa statistics. Therefore, the study is adequately powered to detect a moderate difference in interobserver agreement.
Fleiss’ kappa was used to assess interobserver agreement among the three raters for both WS and TMA datasets, based on the three-category TIL classification. For continuous TIL scores, the intraclass correlation coefficient (ICC) was calculated to evaluate agreement among the three raters before categorization. Cohen’s kappa was applied to assess agreement between each pair of raters for both WS and TMA datasets. Cohen’s kappa measures inter-rater agreement for categorical variables (κ < 0: poor; 0–0.20: slight; 0.21–0.40: fair; 0.41–0.60: moderate; 0.61–0.80: substantial; 0.81–1: Near-perfect). Pearson’s correlation coefficient (R) was also calculated to assess the linear correlation between WS and TMA TIL percentages for each observer.
All statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC). A two-tailed P < 0.05 was considered statistically significant.
RESULTS
Case inclusion and exclusion criteria
A total of 100 cases were initially collected for the study. After excluding cases with inadequate TMA cores (n = 12), missing whole-section slides (n = 8), or incomplete clinicopathological data (n = 4), 76 cases were deemed evaluable and included in the analysis.
TIL assessment results
H&E-stained WSs and TMA cores demonstrated variable lymphocytic infiltration across the cohort. Representative examples of high (≥50%), intermediate (20–49%), and low (<20%) TIL densities are shown in Figure 1a-c, respectively. High TIL cases exhibited dense stromal lymphocytic infiltration with extensive distribution across tumor nests, whereas low TIL cases showed sparse peritumoral lymphocytes.
Interobserver agreement
Cohen’s Kappa (pairwise agreement)
Interobserver agreement for WS slides using Cohen’s kappa was as follows:
Observer 1 versus Observer 2: κ = 0.264
Observer 1 versus Observer 3: κ = 0.288
Observer 2 versus Observer 3: κ = 0.199.
These values indicate fair agreement among raters on WS slides.
For the TMA dataset, Cohen’s kappa scores were as follows:
Observer 1 versus Observer 2: κ = 0.531
Observer 1 versus Observer 3: κ = 0.489
Observer 2 versus Observer 3: κ = 0.539.
These values reflect moderate agreement among observers when scoring TMA slides.
A full summary is presented in Table 1.
| Observers | WS slide (Agreement) | TMA slide (Agreement) |
|---|---|---|
| Observers 1 and 2 | 0.264 (Fair) | 0.531 (Moderate) |
| Observers 1 and 3 | 0.288 (Fair) | 0.489 (Moderate) |
| Observers 2 and 3 | 0.199 (Fair) | 0.539 (Moderate) |
WS: Whole sections, TMA: Tissue microarray
Fleiss’ Kappa (overall agreement)
Overall interobserver agreement among the three raters, as measured by Fleiss’ kappa, was as follows:
WS slides: κ = 0.219 (95% confidence interval [CI]: 0.114– 0.324) → fair agreement
TMA slides: κ = 0.394 (95% CI: 0.258–0.530) → moderate agreement.
These results demonstrate improved interobserver concordance when using TMAs compared to WS slides.
ICC
The ICC assessing agreement among the three raters for continuous TIL scores was 0.6035 for WS slide evaluations and 0.686 for TMA evaluations, both indicating moderate agreement.
When comparing WS and TMA scores for individual observers:
Observer 1 demonstrated strong agreement and a very strong correlation between WS and TMA assessments.
Observer 2 showed slight agreement and moderate correlation, suggesting some inconsistency in scoring between the two modalities.
Observer 3 exhibited moderate agreement and moderate correlation, reflecting a reasonable level of consistency, although lower than Observer 1. WS versus TMA agreement for each observer is summarized in Table 2.
| Statistic | Observer | Value (P) | Agreement/Correlation |
|---|---|---|---|
| Cohen’s kappa | Observer 1 | 0.769 (P<0.0001) | Strong |
| Cohen’s kappa | Observer 2 | 0.203 (P=0.018) | Fair |
| Cohen’s kappa | Observer 3 | 0.508 (P<0.0001) | Moderate |
| Pearson’s R | Observer 1 | 0.947 (P<0.0001) | Very strong |
| Pearson’s R | Observer 2 | 0.542 (P<0.0001) | Moderate |
| Pearson’s R | Observer 3 | 0.637 (P<0.0001) | Moderate |
DISCUSSION
Interobserver agreement
This study evaluated interobserver agreement in TIL scoring using two distinct approaches: WS and TMAs. The findings offer important insights into the reproducibility of TIL assessment and the challenges affecting observer consistency. The interobserver agreement for WS (Cohen’s kappa between 0.199 and 0.288) suggests only fair agreement, which is consistent with some reports about BC and other tumor types. For example, in the Danish study conducted by Tramm et al., kappa values were in the range of 0.38–0.46, corresponding to a fair to moderate agreement.[23] Similarly, studies evaluating TILs in colorectal cancer (CRC) show moderate to fair interobserver agreement using different grading systems.[24-27] A likely contributor to variability in our cohort is the difference in experience among observers, with senior pathologists typically demonstrating more consistent scoring.
TIL assessment on TMAs yielded higher consistency among observers. Cohen’s kappa values ranged from 0.489 to 0.539, suggesting moderate agreement. This trend aligns with previous findings by Kilmartin et al., where reproducibility improved when using limited and defined areas for scoring – akin to the constrained fields in TMAs.[28] However, other reports, for example, a study by Reznitsky et al., evaluated TILs’ reproducibility in HER2-positive BC using both WSs and TMAs, reporting an ICC of 0.93 for WSs versus 0.73 for TMAs, and kappa values of 0.75 and 0.33, respectively. These results showed significantly better reproducibility for WSs than TMAs – contrary to our findings in TNBC. This discrepancy may stem from differences in tumor biology, pathologist experience, or scoring intervals. Furthermore, Reznitsky et al. highlighted the impact of tumor heterogeneity and emphasized that TMAs must represent the full tumor architecture and microenvironment to be reliable. Their conclusion that WSs offer acceptable reproducibility while
TMAs do not underscores the importance of contextualizing scoring platforms within tumor subtype and study design.[29]
The ICC in our study indicated moderate to good reliability. For WS, the ICC was 0.6035, and for TMAs, it was 0.686, indicating more reliability in TMAs. These findings align with other studies in BC and CRC, where ICC values for TMA assessments generally fall within similar ranges. For instance, in a study by Koo and Li, ICC values for scoring TILs in BC were similarly moderate, reflecting the complexity of accurately assessing TIL density across WS.[30] The higher ICC for TMAs in our study supports the hypothesis that TMAs provide a more standardized and reliable method for evaluating TILs due to their reduced complexity and more controlled sampling process.
Likewise, other various studies report higher ICCs for TMAs due to their constrained and uniform sampling compared to WS, where variability in tumor heterogeneity can reduce consistency.[31,32]
The kappa values of TMAs (0.531, 0.489, and 0.539) represent moderate agreement, which aligns with reports suggesting better reproducibility for smaller, more focused tissue regions like TMAs.[33]
Our Fleiss’ kappa of 0.219 for WS and 0.394 for TMAs also aligns with the findings that TMAs typically provide more consistent results across observers.
Studies about immunohistochemical scoring on TMAs showed better results, especially when used by young pathologists with less expertise, perhaps due to their reduced complexity.[34] The reduced complexity and the limited tissue available on the TMA necessitate a simpler analysis and offer less intricate images for evaluation, thus enabling pathologists to obtain very similar results.
Our study highlights a notable discrepancy between TIL assessments in WSs and TMAs, with ICC for matched samples at 0.64 (95% CI: 0.55–0.71). This is comparable to results from other studies, which reported similar ICC values and emphasized the need for caution when extrapolating TIL data from TMAs to whole-section equivalents.[29]
In addition, another study comparing TMA to WS showed that the concordance rate between TMA and WS was only 0.26.[33] This is mainly due to the fact that TMAs are limited in mirroring the tumor heterogeneity since the larger surface and potential tumor heterogeneity presented in WS assessment may account for this variability, as observers may interpret TIL density differently across regions of different tumor composition.[28]
Consistent with findings in the literature, our results reinforce the notion that TIL evaluation in TMAs is less concordant and may not fully align with data obtained from WSs. Notably, studies have shown that reducing categories (e.g., dichotomizing TIL scores into “high” and “low”) can improve interobserver agreement in TMAs, but this simplification may compromise clinical nuance.[23,35,36]
The reduced reproducibility in TMAs can be attributed to their limited sampling area, which may not adequately represent the full spectrum of TIL distribution across the tumor. Studies suggest that full-section evaluation is more reliable for capturing the complex interactions between tumor and immune cells, making it the preferred method in both research and clinical settings.[37-39]
Moreover, while immunohistochemical staining methods in TMA-based studies have demonstrated higher concordance,[34] the use of H&E staining in TMAs remains challenging, with lower ICCs and kappa values observed across multiple studies.[26,40]
Interclass agreement
TMA assessments yielded moderate agreement, with Cohen’s kappa values between 0.489 and 0.539. This, as previously mentioned, is consistent with previous studies suggesting that TMA offers better reproducibility due to its reduced tissue heterogeneity and standardized tissue sampling.[41,42] TMAs allow for the evaluation of a limited, predefined portion of the tumor, reducing the subjective nature of selecting tumor regions to score.[28,43] These results are likely due to the fact that tissue cores from TMAs are more likely to be homogenous.
In line with this, the interclass agreement, as measured by Fleiss’ kappa, was fair for both WS (0.219) and TMAs (0.394), further emphasizing the moderate reliability of TMA-based assessments. These results are similar to findings in the literature, where TMA has been shown to improve reproducibility compared to whole-section slide evaluations, although substantial interobserver agreement remains challenging across most tumor types.[27,44]
In BC, particularly TNBC, agreement was better for continuous measures of stromal TILs (ICC: 0.634, 95% CI: 0.539–0.735), but binary cut points resulted in poorer reliability. These findings are consistent with other studies reporting substantial interobserver variability, with ICCs ranging widely from 0.376 to 0.947. The variability observed emphasizes the need for standardization in TIL quantification to improve reproducibility and clinical utility.[28,44] Reducing complexity by dichotomizing TIL scores (e.g. “high” vs. “low”) improved agreement, suggesting potential pathways to enhance reliability.[36,45]
The discrepancies between WSs and TMAs, and between different staining methods, are critical considerations. WS provides a more comprehensive assessment of the tumor immune contexture, while TMAs, despite their efficiency, may fail to capture intratumoral heterogeneity.[28]
In this study, there are several notable limitations to consider. First, the sample size of 76 evaluable cases, although sufficient for preliminary analysis, may limit the generalizability of our results. Larger, multicenter studies are needed to validate these findings across broader populations and institutions. Second, observer training and variability in experience may have influenced scoring reproducibility. Structured calibration sessions or digital tools may help mitigate this limitation in future studies.
SUMMARY
Interobserver variability remains a key challenge in TIL scoring. While TMAs may reduce variability through standardized and simplified sampling, they do so at the expense of capturing tumor heterogeneity. WSs remain superior for representing the tumor immune contexture. Future efforts should focus on standardizing scoring protocols and incorporating digital image analysis or artificial intelligence tools to enhance accuracy and reproducibility in TIL evaluation.
AVAILABILITY OF DATA AND MATERIALS
The datasets and materials used and analyzed during the present study are available from the corresponding author on reasonable request.
ABBREVIATIONS
DFS: Disease-free survival
FFPE: Formalin-fixed paraffin-embedded
H&E: Hematoxylin and eosin
ICC: Intraclass correlation coefficient
IRB: Institutional Review Board
OS: Overall survival
pCR: Pathological complete response
TILs: Tumor-infiltrating lymphocytes
TMA: Tissue microarray
TNBC: Triple-negative breast cancer
WS: Whole sections
AUTHOR CONTRIBUTIONS
MS: Contributed the concept and the design of the study, case analysis, data analysis, and interpretation; BM, ES, FB, AA: Contributed to study conception, design, case review, and data interpretation; BM, AA, ES: Drafted the manuscript; MS and FB: Critically reviewed and revised the manuscript for important intellectual content. All authors reviewed and approved the final version of the manuscript and meet the ICMJE authorship criteria. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work will be appropriately investigated and resolved.
ACKNOWLEDGMENT
Not applicable.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Ethical approval was obtained from the Institutional Review Board (IRB) of King Hussein Cancer Center. Reference number: [24 KHCC 78]. This study used anonymized archival material. The IRB granted a waiver of informed consent.
CONFLICT OF INTEREST
Given his role as editorial member, Maher A. Sughayer had no involvement in the peer-review of this article and has no access to information regarding its peer-review.
EDITORIAL/PEER REVIEW
To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double-blind model (authors are blinded from reviewers and vice versa) through an automatic online system.
FUNDING: Not applicable.
References
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156:1336-46.
- [CrossRef] [Google Scholar]
- Available from: https://gco.iarc.fr [Last accessed on 2025 Jun 19]
- Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer [Last accessed on 2025 Jun 19]
- Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008;22:1233-9. discussion 1239-40, 1243
- [Google Scholar]
- Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14:R3.
- [CrossRef] [PubMed] [Google Scholar]
- Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv Transl Res. 2018;8:1483-507.
- [CrossRef] [PubMed] [Google Scholar]
- Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
- [CrossRef] [PubMed] [Google Scholar]
- Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018;17:99.
- [CrossRef] [PubMed] [Google Scholar]
- Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11:479-97.
- [CrossRef] [PubMed] [Google Scholar]
- Understanding metastasis: Current paradigms and therapeutic challenges in breast cancer progression. RCSI Stud Med J. 2010;3(1):56-60.
- [Google Scholar]
- Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158-65.
- [CrossRef] [PubMed] [Google Scholar]
- Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
- [CrossRef] [PubMed] [Google Scholar]
- The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68:5405-13.
- [CrossRef] [PubMed] [Google Scholar]
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40-50.
- [CrossRef] [PubMed] [Google Scholar]
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-66.
- [CrossRef] [PubMed] [Google Scholar]
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397-404.
- [CrossRef] [Google Scholar]
- Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the Keynote-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) Cancer Res. 2020;80:PD5-3.
- [CrossRef] [Google Scholar]
- Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541-57.
- [CrossRef] [PubMed] [Google Scholar]
- Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-7.
- [CrossRef] [Google Scholar]
- Mismatch repair protein deficiency in triple-negative breast carcinomas. J Int Med Res. 2024;52(6):3000605241259747.
- [CrossRef] [PubMed] [Google Scholar]
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259-71.
- [CrossRef] [PubMed] [Google Scholar]
- Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: An evaluation of inter-observer agreement between pathologists. Acta Oncol. 2018;57:90-4.
- [CrossRef] [PubMed] [Google Scholar]
- A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One. 2018;13:e0192744.
- [CrossRef] [PubMed] [Google Scholar]
- The tumor microenvironment and immune response in breast cancer. Int J Mol Sci. 2024;25:914.
- [CrossRef] [PubMed] [Google Scholar]
- Validation of tissue microarray technology in ovarian cancer: Results from the nurses' health study. Cancer Epidemiol Biomarkers Prev. 2008;17:3043-50.
- [CrossRef] [PubMed] [Google Scholar]
- Assessment of the tumor-stroma ratio and tumor-infiltrating lymphocytes in colorectal cancer: Inter-observer agreement evaluation. Diagnostics (Basel). 2023;13:2339.
- [CrossRef] [PubMed] [Google Scholar]
- Intra-tumour heterogeneity is one of the main sources of inter-observer variation in scoring stromal tumour infiltrating lymphocytes in triple negative breast cancer. Cancers (Basel). 2021;13:4410.
- [CrossRef] [PubMed] [Google Scholar]
- Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections. APMIS. 2022;130:545-50.
- [CrossRef] [PubMed] [Google Scholar]
- Tumor-infiltrating lymphocytes in breast cancer: Evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies. Am J Clin Pathol. 2018;150:441-50.
- [CrossRef] [PubMed] [Google Scholar]
- Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. 2019;10:71.
- [CrossRef] [PubMed] [Google Scholar]
- Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2019;25:1526-534.
- [CrossRef] [PubMed] [Google Scholar]
- Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Res. 2019;21:151.
- [CrossRef] [PubMed] [Google Scholar]
- Validity and reproducibility of immunohistochemical scoring by trained non-pathologists on tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2021;30:1867-74.
- [CrossRef] [PubMed] [Google Scholar]
- Tumor-infiltrating lymphocytes (TILs) in breast cancer: Prognostic and predictive significance across molecular subtypes. Biomedicines. 2024;12:763.
- [CrossRef] [PubMed] [Google Scholar]
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.
- [CrossRef] [PubMed] [Google Scholar]
- Single-cell spatial analysis of tumor and immune microenvironment on whole-slide image reveals hepatocellular carcinoma subtypes. Cancers (Basel). 2020;12:3562.
- [CrossRef] [PubMed] [Google Scholar]
- Multiplex immunofluorescence and the digital image analysis workflow for evaluation of the tumor immune environment in translational research. Front Oncol. 2022;12:889886.
- [CrossRef] [PubMed] [Google Scholar]
- Whole-slide image analysis reveals quantitative landscape of tumor-immune microenvironment in colorectal cancers. Clin Cancer Res. 2020;26:870-81.
- [CrossRef] [PubMed] [Google Scholar]
- Concordance between Three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) in a multicenter study. Diagnostics (Basel). 2022;12:477.
- [CrossRef] [PubMed] [Google Scholar]
- Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: A multi-institutional study. Breast Cancer Res Treat. 2018;171:1-9.
- [CrossRef] [PubMed] [Google Scholar]
- Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of international TILs working group 2014. Ann Diagn Pathol. 2018;35:77-9.
- [CrossRef] [PubMed] [Google Scholar]
- Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the international TILs working group. Ann Surg Oncol. 2016;23:2242-8.
- [CrossRef] [PubMed] [Google Scholar]
- Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer. Indian J Pathol Microbiol. 2018;61:181-6.
- [CrossRef] [Google Scholar]
- Interobserver agreement of PD-L1/SP142 immunohistochemistry and tumor-infiltrating lymphocytes (TILs) in distant metastases of triple-negative breast cancer: A proof-of-concept study. A report on behalf of the international immuno-oncology biomarker working group. Cancers (Basel). 2021;13:4910.
- [CrossRef] [PubMed] [Google Scholar]

